IN THE SPOTLIGHT

EGFR orchestrates neutrophil activation and NETosis via CEBPβ-dependent PGLYRP1 induction

EGFR orchestrates neutrophil activation and NETosis via CEBPβ-dependent PGLYRP1 induction

EGFR variant profiles in lung adenocarcinoma from different regions of Brazil: a multi-institutional study using a rapid RT‒PCR platform

EGFR variant profiles in lung adenocarcinoma from different regions of Brazil: a multi-institutional study using a rapid RT‒PCR platform

De Novo Germline L858R EGFR Variants and Generalized Acanthosis Nigricans

De Novo Germline L858R EGFR Variants and Generalized Acanthosis Nigricans

EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge

EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge

Phase 2 Trial Explores Osimertinib and Savolitinib Combination for NSCLC Patients with EGFR Mutations and MET Aberrations

Phase 2 Trial Explores Osimertinib and Savolitinib Combination for NSCLC Patients with EGFR Mutations and MET Aberrations

Glomerular hyperfiltration defined by eGFR and long-term clinical outcomes: a systematic review and meta-analysis

Glomerular hyperfiltration defined by eGFR and long-term clinical outcomes: a systematic review and meta-analysis

Development of an APC and TP53-based duplex sequencing assay to positively predict colorectal cancer response to anti-EGFR therapy

Development of an APC and TP53-based duplex sequencing assay to positively predict colorectal cancer response to anti-EGFR therapy

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

Correction to: Local cranial radiation combined with third-generation tyrosine kinase inhibitors improve leptomeningeal metastasis disease-free survival in patients with EGFR-mutated non-small cell lung cancer and brain metastasis

Correction to: Local cranial radiation combined with third-generation tyrosine kinase inhibitors improve leptomeningeal metastasis disease-free survival in patients with EGFR-mutated non-small cell lung cancer and brain metastasis